Module 5

COLLEGE OF NURSING AND PHARMACY
C-PPD1 – DISPENSING 1 (DISPENSING PROCESS, READING &

INTERPRETING THE PRESCRIPTION AND OTHER MEDICINE ORDERS)
First Semester | AY 2021-2022
Module 5: Administrative Orders

Time Frame: Week 10 (4hours)
Schedule of synchronous sessions:
Mapped Learning Outcomes and Course Content for C-PPD1 Dispensing 1, Module 5
Target Learning Outcomes Content and Activities
Hour (At the close of the period allotted, Online Session Offline Session
students should have :)
4 hours  Summarize the different Interactive lecture: Assignment: Review in advance and
DOH and FDA Administrative prepare for recitation
administrative orders Orders
relevant to pharmacy
practice. -E.O 302
-A.O 55 & 64
-M.C 17
1. Content / Discussion / Learning Resources / Link
MALACAÑANG
Manila
BY THE PRESIDENT OF THE PHILIPPINES
EXECUTIVE ORDER NO. 302
DECLARING AND ADOPTING THE PHILIPPINE PHARMACOPEIA AS THE OFFICIAL BOOK OF STANDARDS AND
REFERENCE FOR PHARMACEUTICAL PRODUCTS AND CRUDE PLANT DRUGS IN THE PHILIPPINES
WHEREAS, it is State Policy under Article II, Section 15 of the 1987 Constitution to "protect and promote the right
to health of the people and instill health consciousness
among them";
WHEREAS, the 1987 Constitution also provides in Article XIII, Section 12, that: "The State shall establish and
maintain an effective food and drug regulatory system and undertake appropriate health manpower development
and research, responsive to the
country’s health needs and problems";
Faculty: Jethro M. Ocampo, RPh Page 1 of 22

WHEREAS, a national pharmacopeia that adequately establishes standards for drug/drug products and crude
drugs available for commerce in the Philippines is essential to the attainment of an effective regulatory and health
care delivery systems and addresses the foregoing constitutional mandates;
NOW, THEREFORE, I GLORIA MACAPAGAL-ARROYO, President of the Philippines, do hereby order:
SECTION 1. The Philippine Pharmacopeia (PP) 1 edition April 2004 and any supplement thereto, is hereby
st
declared and adopted as the official book of the standards and references for the determination of the identity,
purity, and quality of pharmaceutical products and crude plant drugs in the Philippines.
SECTION 2. For pharmaceutical products and crude plant drugs that are not listed in the PP, reference maybe
made to the latest editions of United States Pharmacopeia/National Formulary (USP/NF), Japanese Pharmacopeia
(JP), British Pharmacopeia (BP) European Pharmacopeia (EP), and International Pharmacopeia (IP) and other
books of standards and references as maybe recognized and adopted by the
Bureau of Food and Drugs from time to time.
SECTION 3. All orders, issuances, rules and regulations, or parts thereof inconsistent
with this Executive Order are hereby repealed or modified accordingly.
SECTION 4. This Executive Order shall take effect fifteen (15) days after publication in
the Official Gazette.
Done in the City Manila this 29 day of March, in the year of Our Lord, two thousand and four.
th
(Sgd.) GLORIA MACAPAGAL-ARROYO
President
By the President:
(Sgd.) ALBERTO G. ROMULO
Executive Secretary

Republic off the Philippines
Department of Health
OFFICE OF THE SECRETARY
Manila
December 7, 1988

ADMINISTRATIVE ORDER
No. 55 s. 1988
SUBJECT: REQUIREMENTS FOR LABELLING MATERIALS OF
PHARMACEUTICAL PRODUCTS
SUMMARY: In pursuant to the "Foods, Drugs and Devices, and
Cosmetics Act" and the "Generics Acts of 1998", it is required
that the generic name shall be the one with the highest point size
among the printed elements of the label, printed in full and
enclosed exclusively by an outlined box. If the product is
identified by a brand name shall be one point size bigger (generic name) but in
the same typeface, font and color as the brand name and shall
appear immediately above the latter.
Pursuant to R.A No. 3720 as amended by Executive order No. 175, otherwise known as the
"Foods, Drugs and devices, and Cosmetic Act", and R.A No 6675, otherwise known as the
"Generic Act of 1988", the following requirements for the labelling of pharmaceutical products
are hereby promulgated of the information, guidance and compliance of all concerned;

Section 1. Definition of Terms (paki highlight na lang)

For purposes of this regulation the terms


1.1. "Labelling materials" includes the label on the immediate container, and the other
printed materials that are made available with the product at the time of purchase
and/or where the product is used, such as the outer wrapper cartons, leaflet/package
insert accompanying the product, which provide the accurate and necessary detailed
information for the identification and proper used of the product.

1.2. "Product" refers to pharmaceutical products which mean any pharmaceutical or
biological product intended for used in the diagnosis, cure mitigation, treatment or
prevention of disease in human, or to affect the structure or any function of the
human body.
1.3. "Brand Name" refers to the proprietary/trade name assign to the product by the drug
establishment.
1.4. "Generic Name" refers to the identification of drugs and medicines by their
scientifically and internationally recognized active ingredients determined by the
Bureau of Food and Drugs of the DOH.
1.5. "Pharmacologic category" refers to the classification of the product based on its
therapeutic action as specified in the product registration.
1.6. "Formulation" refers to the name (s) and amount (s) of active medicinal ingredients
per dosage unit expressed in the metric system.
1.7. "Indication" refers to the approved clinical use of the product based on substantial
and scientifically supported evidence of the safety and efficacy of the drug in the
given dosage form.
1.8. "Dosage Form" means the pharmaceutical form of the preparation based on official
pharmacopoeia.
1.9. "Mode of administration" refers to the site and manner the product is to be
introduced in to or applied on the body.

1.10. "Warnings" refers to statements regarding the occurrence of potential hazards and
side effects associated with the use of the product and the limitation of its use.
1.11. "Contraindications" refers to statements regarding the conditions wherein the use of
the product may cause harm to the patient.
1.12. "Precautions" refers to the instruction and special care required in the used of the
product to avoid undesired effects and to ensure the safe and effective use of the
drug.
1.13. "Date of manufacture" for products other than biological products means the date
(month and year) during which processing of the bulk product, from which the goods
are to be filled, is completed.
1.14. "Batch number" refers to any distinctive combination of letters and/or numbers,
assigned to a particular batch herein defined as any product produced during a given
cycle of manufacture. The batch number permits the production history of the batch
including all stages of manufacture and control, to be traced and reviewed.
1.15. "Lot number" refers to any distinctive combinations of letters and/or numbers
assigned to a particular lot, herein defined as a portion of a batch.
1.16. "Expiration" or "expiry date" refers to the date after which the product is not
expected to retain its claimed safety, efficacy and quality or potency or after which it
is not permissible to sell, distribute or use said product.
1.17. "Net Content" refers to the total amount/quantity/number of the dosage form in a
certain container of a product expressed in metric system.
1.18. "Storage condition" refers to the prevailing specified range temperature, humidity
and other environmental factors within which optimal stability of the product is
ensured based on laboratory data.
1.19. "Principal display panel" refers to the part of a label that is most likely to be
displayed, presented, shown or examined under customary condition of display for
retail use.

1.20. "Area of the principal display panel" refers to the area or surface of the
container/package where the principal display panel is located.
1.21."Primary pack" is the first pack containing the individually wrapped products, strip
blister packs.
Section 2. General Requirements
2.1 The minimum mandatory information that shall be included in the labelling materials are:

2.1.1 Name of the product (Generic name alone or with Brand name, as the case may
be)
2.1.2 Dosage form and strength
2.1.3 Pharmacologic category
2.1.4 Rx symbol, in case of prescription drugs
2.1.5 Name and complete address of manufacturer and trader, when applicable
2.1.6 Net content
2.1.7 Formulation
2.1.8 Indication(s)
2.1.9 Contraindication(s), precaution(s), warning(s)
2.1.10 Mode of administration/directions for use
2.1.11 Batch and lot number
2.1.12 Expiry/ expiration date and date of manufacture
2.1.13 Registration number
2.1.14 Storage conditions
2.1.15. (For Rx products) Foods, drugs and devices and Cosmetic Act prohibits
dispensing without prescription (Amended! By AO 64 p 212) (added prohibition
for List A and List B found on that AO)


2.2. All information required to appear on the label must be:

2.2.1 Written in English or Filipino
2.2.2 Clearly and prominently displayed
2.2.3 Readable with normal vision without straining. The color contrast, the position and
spacing of the information must be taken into consideration in complying with
labelling requirements.

2.3. The principal display panel must:
2.3.1 Contain the particulars required under 2.1.1 to 2.1.6
2.3.2. Comprise 40% of the total surface of the container, except in the case of the
rectangular container where the total area of the principal display panel must
equal to the product of the height and width of the entire side of the container.
For any other shaped container presenting an obvious principal display panel
such as the top of a triangular or circular container, the size of the area shall
consist of the entire top surface.
2.4 On the label of the immediate container outside of the principal display panel will appear the
following information: (mga hindi kasama sa anim)

2.4.1.Formulation
2.4.2.Indication(s)
2.4.3.Mode of administration/directions (s) for use
2.4.4.Batch and lot number
2.4.5.Expiry/ expiration date and date of manufacture

2.4.6.Registration number
2.4.7.Storage conditions
2.4.8.(For Rx) Foods, Drugs and devices and Cosmetic Act prohibits dispensing without prescription

2.5. Other information and additional detail shall appear on the other labeling materials such as
inserts/leaflets or wrapper cartons.
Section 3. Specific Requirements (Refer to 2.1= Iisa-isahin)
3.1. Name of the product
3.1.1. In all cases, the generic name shall be the prominently printed element on the
label, defined as the one with the highest point size among the various printed
elements on the label. It shall be enclosed exclusively by an outline box rendered in the
same color as the generic name. The background color inside the box, against with the
generic name is rendered, should be the same color as the background color outside
the box, against which the brand name is rendered.

3.1.2. In all cases, the generic name shall be printed in full, not abbreviated and in
accordance with the International Non-proprietary Name (INN). In case the salt or the
specific chemical form of the drug needs to be indicated, this must be included inside
the box but in smaller point size.

3.1.3. If a product is identified by a brand name together with its generic name, the
following shall be required in addition to 3.1.1 and 3.1.2.
3.1.3.1 The generic name and brand name shall be rendered using the same
typeface, font and color, with the generic name appearing immediately above

the brand name and rendered in a point size bigger than the brand name

3.1.3.2 If a brand name is presented using a special typeface exclusively
designed and used for it, the generic name shall be rendered in Helvetica
Medium or Universe Medium while complying with the other pertinent
provisions above.

(3.1.4 and 3.1.5 are amended by AO 64, They are joined together)
3.1.4. Products containing two (amendment: TWO OR MORE)active ingredients
shall have the generic name of both active ingredients indicated within the box for
generic name. (amendment = shall have name determined by FDA)
(3.1.5 is removed)
3.1.5. For products containing three or more active ingredients an official name for the
combination, which shall serve as the equivalent of the generic name, shall be
designated by a BFAD committee of experts. The starting date for the use of this official
name on the label shall be in accordance with a schedule to be determine by BFAD.
3.2. Dosage form shall be specified such as tablets, capsules, syrups, suspensions, ointments,
including special delivery system such as sustained release, etc.
3.3 Pharmacologic category shall conform to the category used in the Philippine National Drug
Formulary attached as Annex "A"(later)(point out) provided that drugs which cannot be classified under this
categories may be given a therapeutic category other than what appears in the Annex subject
to the approval of BFAD taking into consideration current acceptable standards for therapeutic
categories.


3.4. Rx symbol

3.4.1. The Rx symbol must be printed in a contrasting color to the background on which
it appears.
3.4.2. Over printing or superimposition of the Rx symbol is allowed provided that such
will not result in obliterating or rendering less legible the other required label
requirements.
3.4.3. The Rx symbol should be printed in a type size no less than one fifth (1/5) of the
height of the principal displayed panel.

3.5. Complete name and address of manufacturer and also trader, when applicable, must
appear on the principal display panel of the label.

3.6. Net content shall indicate the total amount/quantity/number of the dosage form in a given
container of the product expressed in metric system.

3.7. Formulation

3.7.1. Active ingredient(s) must be stated in their generic names (INN).

3.7.2. The amounts of the active ingredient(s) shall be expressed in the metric system (3720)
or unit of potency, when applicable, as specified in the official compendia.

3.7.3. The salt or chemical form(s) of active ingredient(s) must be stated, when
applicable.

3.7.4. Multiple components must be enumerated in the order of decreasing
pharmacologic activity, when applicable.
3.7.5. The coloring agent and other excipients used in the formulation that may cause
hypersensitivity and/or other adverse reaction(s) must be indicated.

3.7.6. The alcohol content when present must be expressed in percent (%).

3.8. Indication shall state only the approved clinical use(s) of the product as stated in the
approved BFAD registration.

3.9 Contraindication(s), Precaution(s), Warning(s)

3.9.1. Full information regarding contraindication(s) to the use of drugs, as well as
precaution(s) to be observed in its administration and use must be provided.

3.9.2 Warning statements, as required, and specified by BFAD, must be stated.
ANNOTATION: The FDA may prescribe certain labelling information to be indicated on the label of
certain drug products.

One of this instances is the information required to be printed of the label of isopropyl
alcohol 70% or preparations using isopropyl alcohol.

On May 28, 1985 BFAD has required that preparations using isopropyl alcohol must be
indicated on its label the following additional information:


1) "For use in the hospital or sickroom as a rundown or for general massage purposes. This
compound made from isopropyl alcohol does not contain nor is it offered as a substitute for
ethyl or grain alcohol."
2) "FLAMMABLE."
3) "WARNING: For External Use Only." (To be printed in red color) and also, "Keep out of
reach of Children."
Specific labelling requirements for specific products may come in the form of a
Memorandum Circular which one may find in the chapter 6 of Banned or Restricted Drugs
or Products.

3.10. Mode of Administration/Directions for Use
3.10.1. Full information must be provided for the recommended dosage, including the
initial dose, the optimal use or usual dose, frequency interval, the duration of treatment,
dosage adjustment or other pertinent aspects of drug therapy.

3.10.2. Relevant information regarding dilution, reconstitution, preparation and
administration must be included.

3.10.3. Separate directions for adults and children, must be stated, and if not
recommended for the children, the dosage shall be clearly identified as "adult dose".
3.11. Batch/Lot Number

3.11.1. If the entire batch is marketed under one company, only the batch number
needs to be indicated. If however, a batch is divided into several lots are marketed by
different companies, the lot number and its corresponding batch number shall be
indicated for every lot.

3.11.2. The batch and/or lot number must be printed on each strip of ten (10) blister
units.
3.12. Expiry/Expiration Date

3.12.1. The expiry or expiration date shall be expressed in terms of the month and the
year. In such cases, the last day of the month is assumed as the expiration date.

3.12.2. For a drug that is reconstituted prior to use, a period of guaranteed efficacy
must be specified at a given storage condition.
3.12.3. The expiration date shall be printed or embossed on the tin foil, blister and/or
strip package.
3.13. Registration number shall indicate the drug registration number and code assigned by
BFAD.

3.14. Storage conditions appropriate for the product must be stated.
Section 4. Biological Products

For biological products, the label must include, in addition to the requirements of Section 2 and
3:

4.1. The name and proportion of any antimicrobial agent in the product.
4.2. The name of any adjuvant in the product or any substance which, when administered with
an antigen, modifies the immune response to that antigen.


4.3. The name of the species of animal or organism from which the product has been prepared.
4.4. For monoclonal antisera, the name of the species source or name of the species of origin
of the hybridoma cell line used in the preparation of the product. (1)

4.5. For viral vaccines produced in animal cells or cell cultures, the name of the cell culture
substrate, or the name of the species of animal and tissue used in the manufacture of the
product, as well as the name of any residual antibiotic present in the product, when
applicable.

4.6. The potency of biological products which needs to be prepared before use, shall be
expressed as potency unit or weight of active substances per dose.

4.7. The potency unit to be used shall be the International Unit has been established, the
potency unit to be used shall be that approved by the BFAD taking into consideration
current acceptable standards.

4.8. Date of manufacture which pertains to the date (month and year) of the latest quality
control analysis performed on the product provided the product has been stored under
conditions which have been shown to preserve the potency of the product.
Section 5. Injections

In addition to the requirements referred to in Section 2 and 3, when the product is an injection,
the label shall include:

5.1. The name and quantity of all excipients in the product except where Section 6 applies (LVP).
5.2. A statement of the recommended routes of administration such as "intravenous",
"intramascular", or "subcutaneous".

5.3. Where an antimicrobial agent is not included in the product, the words "Use only once or
discard any remaining portion" or words to that effect.

5.4. Where the contents of the container are to be used on one occasion only, the words "single
use" or "single dose".
5.5. Where the products consist of a concentrated solution for injection, a direction not to
administer the solution undiluted and a direction to dilute the solution with the specified
diluent to the appropriate volume before use. (2)
Section 6. Large Volume Injections

In addition to the requirements referred to in Section 2 and 3, the label shall include:

6.1. The names and quantities of all excipients and active substances in the nominal volume of
fluid in the container, listed in descending order of magnitude within each group of
chemically similar substances.

6.2. Where one or more substances are amino acids and/or protein, a statement of the total
amount of nitrogen in the nominal volume of fluid in the container. (3)

6.3. The nominal osmolality.
6.4. A statement which specifies whether the solution is nominally "hypotonic" or "hypertonic".
6.5. The nominal pH range of the solution.

6.6. The words "single use" or "single dose". IMPT
Section 7. Topical Products

In addition to the requirements referred to in Section 2, and 3, the label shall include the name
and proportion of any antimicrobial agent present in the product.

Section 8. Products for External Use
In addition to the requirements referred to in Section 2 and 3, the statement "FOR EXTERNAL
USE ONLY" printed in red color must appear on the principal display panel of the label.

Section 9. Small Containers
Where the product is enclosed in a container which has a capacity of 10 milliliters or less and
the container is enclosed in a primary pack.
9.1. The label of the container must contain the requirement of 2.1.1(Brand - generic)
company logo, strength, mode of administration, batch number and expiry date.

9.2. The label of the primary pack or other labelling materials must contain the requirements
referred to in Section 2 and 3, and Section 4 and 5, when applicable.

9.3. When it is not practicable to set out particulars in full on a label on the container, the
particulars referred to in 9.1 may be abbreviated, provided the abbreviation is not
ambiguous.
Section 10. Individually Wrapped Products, Strip and Blister Packs

Where the product consist of individual dosage units, and each after which each individuals

dosage unit is enclosed in primary pack:
10.1. The individual wrapper unit must contain the requirements of 2.1.1, company name or
logo, strength and expiry date.

10.2. For products contained in strip or blister packs, the requirements of 2.1.1, strength, and
expiry date must appear for every two units (this is amended by AO 64, it is determined that it is impracticable=
for every strip), and company name and batch number for every strip of 10 units.(Amended= all for each strip)

10.3. The primary pack or other labelling materials must contain the requirements referred to in
Section 2 and 3.
Section 11. Exemptions

11.1. There a container or primary pack containing products is enclosed in a transparent
covering and the particulars which are required to be set out on the label on the container
or primary pack are clearly visible through the transparent covering.

11.2. Where products are made up or compounded by a pharmacist in a accordance with the
individual prescription of a medicinal practitioner, dentist, or veterinarian.

11.3. Where products are used solely for investigational purpose.
11.4. Where products are donated by foreign agencies/ person, the requirements of generic
labelling may be waived except that the expiry date must be indicated.
The requirements of this Regulation do not apply in relation to goods under 11.3, 11.4 and in
exceptional cases where the labelling provisions of this Regulation are not appropriate, but in
this cases exemption must be applied for and approved by BFAD on a case to case basis.

ANNOTATION: The condition under which exemption from generic labelling may be granted are
applicable to all, whether the labels are governed by A.O. 55 s. 88, A.O. 85 s. 90 or A.O.
99 s.90

Section 12. Violative/Prohibited Acts

12.1. Any product that is not labelled in accordance with the requirements of this Regulation
shall be deemed misbranded.

12.2. The following acts and the causing thereof are hereby prohibited:

12.2.1. The manufacture, sale, offering for sale or transfer of any product that is
misbranded.

12.2.2. Forging, counterfeiting, simulating or falsely representing or using any mark,
stamp, label or other identification device required under the Regulation without
proper authority.

12.2.3. The alteration, mutilation, destruction, obliteration or removal of the whole or
any part of the labelling of product, if such act is done while such product is
held for sale and results in such article being misbranded.

12.2.4. The use on the labelling of any product of any representation or suggestion that
an indication with respect to such product is approved by BFAD or that such
product complies with the provisions of this Regulation, when in fact it does
not.

12.2.5. The use, in labelling of product of any reference to any BFAD report or
documents (analysis) without clearance from BFAD.
Section 13. Sanctions

For violation of this Regulation, any or all of the following sanctions after due notice and
summary hearing may be imposed by the Secretary of Health.

13.1. Suspension or revocation of the LTO of drug establishments and outlets and cancellation
of Certificate of Product Registration.
13.2. Imposition of administrative fines of not less than P1,000.00 nor more than P5,000.00.
13.3. Recall from the market of misbranded products(s).
13.4. Confiscation of the violative(s).
Section 14. Criminal Liability

The imposition of the above sanctions does not preclude the institution of appropriate criminal
proceedings pursuant to Section 26 of R.A No. 3720, as amended, and Section 12 of R.A No.
6675.
Section 15. Separability

In case any provision to this rules and regulations is declared contrary to law or
unconstitutional, other provisions which are not affected thereby shall continue to be in force
and in effect.

Section 16. Repealing Clause

All administrative Orders, Rules and Regulations and other administrative issuances or parts
thereof, inconsistent with the provisions of this Regulation, are hereby repealed and modified
accordingly.

Section 17. Effectivity
This regulation shall take effect fifteen (15) calendar days after publication in two newspapers
of general circulation or in the Official Gazette.
Provided, however, (1) that all productions shall
be covered by these rules and Regulations as soon as the manufacturer or trader is ready but
not later than April 1, 1989 except for multiple component products as provided for in 3.1.5; (2)
that drug establishments shall have their new label approved by BFAD starting on the date of
the effectivity of these rules and regulations, provided further, that all drug establishments shall
report to BFAD the first batch number of their production which carries the new label. However,
those product already in the market bearing the old labels on the date of effectivity of this
Administrative Order shall be allowed to remain in the market but not later than December 31,
1989.
(Sgd) ALFREDO R.A. BENGZON
Secretary

ANNOTATION: Drugstores or drug outlets and drug distributors are warned that sale, offer for
sale and distribution of drugs not complying with the requirements of Generic Labelling shall be punishable. (Ref.:
Memorandum Circular No. 1 s. 1990 dated 2.12.90)

REFER to Pharmacologic catergories sa dulo ng AO 55
AND
Sa LIST A (prohibited and regulated) and LIST B (strict precaution sa dulo ng AO 64 s 1989

https://ww2.fda.gov.ph/attachments/article/155171/AO%2064%20Amend%20A.O.%2055%20s.
%201988%20(Requirement%20for%20Labelling%20Materials%20of%20Pharml%20Prods).pdf
REPUBLIC OF THE PHILIPPINES
DEPARTMENT OF HEALTH
BUREAU OF FOOD AND DRUGS
Alabang, Muntinlupa
Metro Manila
August 15,1989
MEMORANDUM CIRCULAR
No. 17 s. 1989
Subject : Monitoring of drugstore pharmacist's office hours
To : All drug outlets, Food and Drug Inspectors and all concerned
This office has received and verified reports that drugstores are in operation outside and beyond the
office hours of the pharmacist which is a violation of Sec. 27 of R.A. 5921 thus:
"Pharmacist required & compensation. - Every pharmacy, drugstore or hospital pharmacy whether owned by the
government or a private person or firm shall at all times when open or business be under the personal and
immediate supervision of a registered pharmacist: Provided: that no pharmacist shall have personal supervision of
more than one such establishment. In cases where a drug establishment
operates in more than one shift must be under the supervision and control of a registered pharmacist.
xxx" (sec 27)
In the interest of the public safety all drugstore are hereby warned to open their drugstores to the public only
with the presence of the BFAD registered managing pharmacist. The drugstore should be closed everytime that
the pharmacist is out, otherwise this office will be constrained to subject the drugstore and the managing
pharmacist to appropriate sanctions.
After the first and second official warnings, the drugstore will be closed temporarily without further notice.
For strict compliance.

(Sgd) CECILE P. GONZALEZ
Director

NOTED :
(Sgd) QUINTIN L. KINATANAR, M.D., Ph.D., CESO I
Assistant Secretary for Standards
and Regulation
2. Evaluation of Learning
For the evaluation of learning for Module 5, a scheduled quiz will be assigned in the Google Classroom and
will be taken before the start of the next Module during the Synchronous Class.
References
Adams, C.H. and Jones, P.D. Therapeutic communication for health professionals (2011/latest edition)
Blenkinsopp, A. and Panton, R. Health promotion for pharmacists (1991/latest edition)
Gupta, GD, NK Jain, Modern Dispensing Pharmacy (2011)
Pharmacists talking with patients: a guide to patient counseling / Melanie J. Rantucci. (2012)
Congratulations for having completed this C-PPD1 Module 5! See you in the next Module

Module 5

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Module 5

Uploaded by

Copyright:

Available Formats

COLLEGE OF NURSING AND PHARMACY

C-PPD1 – DISPENSING 1 (DISPENSING PROCESS, READING &

Module 5: Administrative Orders

1. Content / Discussion / Learning Resources / Link

BY THE PRESIDENT OF THE PHILIPPINES

EXECUTIVE ORDER NO. 302

country’s health needs and problems";

Faculty: Jethro M. Ocampo, RPh Page 1 of 22

NOW, THEREFORE, I GLORIA MACAPAGAL-ARROYO, President of the Philippines, do hereby order:

Bureau of Food and Drugs from time to time.

with this Executive Order are hereby repealed or modified accordingly.

the Official Gazette.

(Sgd.) GLORIA MACAPAGAL-ARROYO

(Sgd.) ALBERTO G. ROMULO

Faculty: Jethro M. Ocampo, RPh Page 2 of 22

Republic off the Philippines

OFFICE OF THE SECRETARY

SUBJECT: REQUIREMENTS FOR LABELLING MATERIALS OF

SUMMARY: In pursuant to the "Foods, Drugs and Devices, and

Cosmetics Act" and the "Generics Acts of 1998", it is required

among the printed elements of the label, printed in full and

enclosed exclusively by an outlined box. If the product is

appear immediately above the latter.

Section 1. Definition of Terms (paki highlight na lang)

For purposes of this regulation the terms

information for the identification and proper used of the product.

prevention of disease in human, or to affect the structure or any function of the

scientifically and internationally recognized active ingredients determined by the

Bureau of Food and Drugs of the DOH.

therapeutic action as specified in the product registration.

per dosage unit expressed in the metric system.

given dosage form.

introduced in to or applied on the body.

Faculty: Jethro M. Ocampo, RPh Page 4 of 22

the product may cause harm to the patient.

are to be filled, is completed.

including all stages of manufacture and control, to be traced and reviewed.

assigned to a particular lot, herein defined as a portion of a batch.

is not permissible to sell, distribute or use said product.

certain container of a product expressed in metric system.

ensured based on laboratory data.

displayed, presented, shown or examined under customary condition of display for

Faculty: Jethro M. Ocampo, RPh Page 5 of 22

container/package where the principal display panel is located.

Section 2. General Requirements

2.1.2 Dosage form and strength

2.1.3 Pharmacologic category

2.1.4 Rx symbol, in case of prescription drugs

2.1.6 Net content

2.1.9 Contraindication(s), precaution(s), warning(s)

2.1.10 Mode of administration/directions for use

2.1.11 Batch and lot number

2.1.12 Expiry/ expiration date and date of manufacture

2.1.13 Registration number

2.1.14 Storage conditions

dispensing without prescription (Amended! By AO 64 p 212) (added prohibition

for List A and List B found on that AO)

Faculty: Jethro M. Ocampo, RPh Page 6 of 22

2.2. All information required to appear on the label must be:

2.2.1 Written in English or Filipino

2.2.2 Clearly and prominently displayed

spacing of the information must be taken into consideration in complying with

2.3. The principal display panel must: